1351 ET - As Centessa Pharmaceuticals reports results and predicts a "data-rich" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. "Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year," the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 "appear to be lower than competitors at same stage of development." TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
March 24, 2025 13:51 ET (17:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。